TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Silo Pharma ( (SILO) ) has issued an announcement.
On October 1, 2025, Silo Pharma closed a securities purchase agreement with institutional investors, selling 2,857,143 shares of common stock at $0.875 per share, raising approximately $2.5 million. The company issued unregistered warrants for additional shares, with proceeds intended for working capital and general corporate purposes. The engagement with H.C. Wainwright & Co. as the exclusive placement agent involved fees and warrants for the agent. This move is part of Silo Pharma’s strategy to strengthen its financial position and support its developmental programs.
More about Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The company focuses on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo Pharma collaborates with leading universities and laboratories for its research.
Average Trading Volume: 1,285,951
Technical Sentiment Signal: Sell
Current Market Cap: $7.09M
For a thorough assessment of SILO stock, go to TipRanks’ Stock Analysis page.